Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Clinical Trial
86%
Atezolizumab
79%
Progression Free Survival
77%
Non Small Cell Lung Cancer
56%
Immune Checkpoint Inhibitor
55%
Adverse Event
55%
Breast Cancer
52%
Melanoma
32%
Inflammatory Arthritis
30%
Rheumatoid Arthritis
30%
Malignant Neoplasm
30%
Proton Pump Inhibitor
30%
Lung Cancer
29%
Vemurafenib
25%
Randomized Controlled Trial
20%
Sorafenib
19%
Neoplasm
18%
Remission
18%
Chemotherapy
17%
Cobimetinib
17%
Combination Therapy
16%
Trastuzumab Emtansine
16%
Clinical Study
16%
Immunotherapy
15%
Abemaciclib
14%
Transitional Cell Carcinoma
14%
Liver Cell Carcinoma
14%
Disease Modifying Antirheumatic Drug
14%
Leflunomide
14%
Multiple Myeloma
14%
Physiologically Based Pharmacokinetic Modelling
13%
Colorectal Carcinoma
12%
Biological Marker
10%
Therapeutic Drug Monitoring
10%
Diseases
10%
Pharmacokinetic Modeling
9%
Dabrafenib
9%
Drug Interaction
9%
Afatinib
9%
Phosphotransferase Inhibitor
9%
Syndecan 1
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
9%
Ritonavir
9%
Disease Activity
9%
Gamma Urogastrone
9%
Tocilizumab
8%
C Reactive Protein
8%
Epidermal Growth Factor Receptor 2
8%
Rash
7%
Medicine and Dentistry
Clinical Trial
66%
Atezolizumab
61%
Overall Survival
55%
Non Small Cell Lung Cancer
42%
Immune Checkpoint Inhibitor
41%
Progression Free Survival
37%
Lung Cancer
32%
Patient-Reported Outcome
29%
Pooled Analysis
27%
Breast Cancer
24%
Medicine
23%
Adverse Event
22%
Proton-Pump Inhibitor
19%
Lung
19%
Clinical Study
18%
Body Mass Index
16%
Immunotherapy
16%
Malignant Neoplasm
15%
Chemoimmunotherapy
14%
Multiple Myeloma
14%
Hazard Ratio
14%
Clinician
14%
Immunity
13%
Oncology
13%
Randomized Controlled Trial
13%
Colorectal Carcinoma
12%
Advanced Cancer
12%
Clinical Prediction Model
11%
Biological Marker
11%
Sortilin
11%
Rheumatoid Arthritis
10%
Combination Therapy
10%
Inflammatory Arthritis
10%
Subgroup Analysis
10%
Melanoma
10%
Immunohistochemistry
10%
Transitional Cell Carcinoma
9%
Prostate Cancer
9%
Health Care Cost
9%
Proportional Hazards Model
9%
Health Care
7%
Lysosome
7%
Meta-Analysis
7%
C Reactive Protein
6%
High Risk Population
6%
Disease Exacerbation
6%
Protein Expression
6%
Cancer
6%
Daratumumab
6%
Electrocorticography
6%
Immunology and Microbiology
Atezolizumab
55%
Overall Survival
48%
Immunity
43%
Progression Free Survival
31%
Inflammatory Arthritis
15%
Leflunomide
15%
Body Mass
14%
Teriflunomide
11%
Blood Plasma
9%
Multiple Myeloma
9%
Arm
7%
C-Reactive Protein
6%
Protein Expression
6%
Immunotherapy
6%
Disease Burden
5%
Daratumumab
5%
Pharmacokinetic
5%